Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare genetic condition causing dramatically accelerated aging in children, and while it remains fatal, an FDA-approved treatment (lonafarnib) now meaningfully extends life expectancy, a significant update to older “no treatment exists” descriptions of this condition. This guide covers the genetics, symptoms, and current treatment landscape.
This is general information, not medical advice.
What causes Progeria
HGPS is caused by a mutation in the LMNA gene, which normally produces a protein called lamin A that helps maintain the structural integrity of the cell nucleus. The mutation causes production of an abnormal version of this protein, called progerin, which accumulates in cells and disrupts normal nuclear function, contributing to the accelerated aging process throughout the body. It occurs in approximately 1 in 4 million births worldwide, with an estimated global prevalence of about 1 in 20 million living individuals, making it one of the rarest genetic conditions known.
Symptoms and features
Children with Progeria typically appear normal at birth and in early infancy, with the condition’s features emerging over the following year or two: growth deficiency and failure to gain weight at the expected rate, hair loss (including scalp hair, eyebrows, and eyelashes), aged-looking skin, loss of fat beneath the skin, joint stiffness and abnormal fibrous tissue around joints, reduced bone density leading to increased fracture risk, and characteristic facial features including a receding chin, thin nose, and prominent eyes. Notably, Progeria does not affect intellectual development or the achievement of developmental motor milestones like sitting, standing, and walking; children with Progeria typically have normal cognitive development throughout their shortened lives.
The most serious complication: early cardiovascular disease
The most life-threatening aspect of Progeria is severe, accelerated hardening of the arteries (arteriosclerosis) beginning in childhood, dramatically increasing the risk of heart attack and stroke at an extremely young age. This cardiovascular complication is the primary cause of death in children with Progeria, and it’s the specific target of the treatment breakthrough described below.
A real treatment breakthrough: lonafarnib
This is an important update that many older descriptions of Progeria miss: in 2012, the first-ever Progeria clinical drug trial demonstrated that lonafarnib, a farnesyltransferase inhibitor, was effective treatment for the condition. The FDA and, separately, the European Medicines Agency (as Zokinvy, in 2022) have approved lonafarnib for patients with a genetically confirmed diagnosis of HGPS or related progeroid laminopathies, for use in children 1 year and older.
Without treatment, children with Progeria historically died of cardiovascular complications at an average age of 14.5 years, with a documented range of roughly 6 to 20 years. With long-term lonafarnib treatment, life expectancy has been shown to increase by an average of about 4.5 years, and cardiovascular health markers significantly improve. This is not a cure, Progeria remains a fatal condition, but it represents genuine, clinically meaningful progress that has changed the treatment landscape since the drug’s approval.
Frequently asked questions
Is there a cure for Progeria?
No, there is currently no cure. However, an FDA and EMA-approved treatment (lonafarnib) has been shown to meaningfully extend life expectancy and improve cardiovascular health, a significant treatment advance since the first successful clinical trial in 2012.
What is the life expectancy for a child with Progeria?
Historically, without treatment, death from cardiovascular complications occurred at an average age of 14.5 years. With long-term lonafarnib treatment, average life expectancy has been extended by about 4.5 years.
Does Progeria affect intelligence or development?
No. Progeria does not affect intellectual development or the achievement of motor milestones like sitting, standing, and walking; affected children typically have normal cognitive development.
What causes Progeria?
A mutation in the LMNA gene, which leads to production of an abnormal protein called progerin that accumulates in and damages cells, driving the accelerated aging process.
How rare is Progeria?
Extremely rare, occurring in approximately 1 in 4 million births, with an estimated 1 in 20 million people currently living with the condition worldwide.